Components covered- EGFR | Mutation Analysis /ALK/ROS1/PDL-1

For identifying non small cell lung cancer patients who could be benefited from TKI therapy.
Aid in identifying patients eligible for treatment with ALK Kinase Inhibitor
To identify NSCLC patients who can derive benefit from crizotinib therapy.